Zydus Lifesciences Limited — Important, 13-08-2025: General Updates

Zydus Lifesciences' Baddi formulation plant has completed a USFDA surveillance inspection, concluding with 4 observations. Significantly, no data integrity issues were identified. The company stated it will work expeditiously to address these. This outcome is a key development for regulatory compliance. Prompt resolution of the observations will ensure uninterrupted product flow to the US market, which is vital for the company's operational stability and revenue outlook.